摘要
目的检测肝细胞癌(HCC)患者射频消融治疗前后血清中磷脂酰肌醇蛋白聚糖3(GPC3)的浓度,初步研究其在疗效评价中的临床应用价值。方法采用酶联免疫吸附法检测59例HCC患者、35例肝硬化患者、30例健康对照组血清中GPC3的表达,其中30例HCC患者经射频消融治疗,对治疗前与治疗后1d、5d、30d血清中GPC3的浓度进行比较。结果 HCC患者血清GPC3浓度明显高于肝硬化患者和健康对照组人群,3组间比较差异有统计学意义(P<0.01),HCC患者射频消融治疗后不同时间点GPC3含量较治疗前均有显著下降(P<0.01)。结论血清GPC3含量升高有助于HCC的诊断,特异性较好,与甲胎蛋白表达无显著相关性,射频消融治疗后不同阶段GPC3均有不同程度降低,在疗效评估中有一定临床价值。
Objective To detect the concentration of Glypican-3（GPC3） in serum before and after the radiofrequency ablation（RFA）treatment for hepatocellular carcinoma（HCC）patients,and determine its clinical value through efficacy evaluation.Methods The concentration of serum GPC3 in 59 patients with HCC,35 patients with cirrhosis and 30 healthy control subjects were assayed with ELISA.The GPC3 levels in their serumbefore treatment,1-day,5-day and 30-day after RFA were compared.Results The concentration of GPC3 in the serum of HCC patients was significantly higher than those in cirrhosis patients and healthy people（P0.01）.Contrasted with those before treatment,the GPC3 content of HCC patients at different times after RFAdecreased（P0.01）.Conclusions The increasing of serum GPC3 content contributed to the diagnosis of HCC,with no significant correlation to AFP expression.Compared with those before treatment,the levels of GPC3 at different times after RFAdecrease.Therefore,the detection of GPC3 is proved to possess good clinical application value.
出处
《中华保健医学杂志》
2013年第3期237-239,共3页
Chinese Journal of Health Care and Medicine
基金
吴阶平基金会肝病医学部(WJP-LD-2012075A)
